+ Watch DRTX
on My Watchlist
Recent open market buys by the CEO primarily. Other directors having also bought doesn't hurt!
Durata has been very weak ahead of the dalbavancin NDA and MAA submissions despite what appears to be solid phase III data and the promise of priority NDA review due to QIDP status. Is the stock weak because no one talks about Durata, since Trius is the antibiotic pump du jour? Or are hedgies and institutions avoiding the stock because of dalbavancin's troublesome provenance and data concerns that aren't being revealed to retail investors? Durata might not get a big run ahead of a dalbavancin PDUFA, but it might be good for at least a 10% bump from the lows.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions